Peptide 021

Last updated

Peptide 021
Peptide021 structure.png
Identifiers
  • (3S)-3-acetamido-4-[[2-[[2-[[(2S)-1-[[(5S,7R)-3-carbamoyl-1-adamantyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-oxobutanoic acid
CAS Number
PubChem CID
Chemical and physical data
Formula C27H42N6O8
Molar mass 578.667 g·mol−1
3D model (JSmol)
  • CC(C)C[C@@H](C(=O)NC12C[C@@H]3C[C@H](C1)CC(C3)(C2)C(=O)N)NC(=O)CNC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)C
  • InChI=1S/C27H42N6O8/c1-14(2)4-18(24(40)33-27-9-16-5-17(10-27)8-26(7-16,13-27)25(28)41)32-21(36)12-29-20(35)11-30-23(39)19(6-22(37)38)31-15(3)34/h14,16-19H,4-13H2,1-3H3,(H2,28,41)(H,29,35)(H,30,39)(H,31,34)(H,32,36)(H,33,40)(H,37,38)/t16-,17+,18-,19-,26?,27?/m0/s1
  • Key:LUJZBZPLIRWWGJ-NBONATBJSA-N

Peptide 021 (Ac-DGGLAG-NH2, P021, GLXC-21260) is a synthetic peptide derivative that is derived from a 4-amino acid active fragment of ciliary neurotrophic factor, which has been substituted with an unnatural adamantane based amino acid residue on the end of the chain. This substitution is highly lipophilic and facilitates transport of the molecule across the blood-brain barrier. It has neurotrophic effects and enhances neurogenesis, and has been investigated for treatment of neurological disorders such as Alzheimer's disease. [1] [2] [3] [4] [5] [6] [7]

See also

References

  1. ↑ Li B, Wanka L, Blanchard J, Liu F, Chohan MO, Iqbal K, et al. (August 2010). "Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice". FEBS Letters. 584 (15): 3359–3365. Bibcode:2010FEBSL.584.3359L. doi:10.1016/j.febslet.2010.06.025. PMID   20600002.
  2. ↑ Bolognin S, Buffelli M, Puoliväli J, Iqbal K (September 2014). "Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound". Neurobiology of Aging. 35 (9): 2134–2146. doi:10.1016/j.neurobiolaging.2014.02.017. PMID   24702821.
  3. ↑ Kazim SF, Blanchard J, Dai CL, Tung YC, LaFerla FM, Iqbal IG, et al. (November 2014). "Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease". Neurobiology of Disease. 71: 110–130. doi:10.1016/j.nbd.2014.07.001. PMID   25046994.
  4. ↑ Kazim SF, Blanchard J, Bianchi R, Iqbal K (April 2017). "Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome". Scientific Reports. 7 45561. Bibcode:2017NatSR...745561K. doi:10.1038/srep45561. PMC   5377379 . PMID   28368015.
  5. ↑ Baazaoui N, Iqbal K (June 2017). "Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound". Alzheimer's Research & Therapy. 9 (1) 45. doi: 10.1186/s13195-017-0273-7 . PMC   5488423 . PMID   28655344.
  6. ↑ Wei W, Liu Y, Dai CL, Baazaoui N, Tung YC, Liu F, et al. (2021). "Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction". Journal of Alzheimer's Disease. 82 (2): 631–646. doi:10.3233/JAD-201599. PMC   8385525 . PMID   34057082.
  7. ↑ Lozupone M, Dibello V, Sardone R, Castellana F, Zupo R, Lampignano L, et al. (May 2023). "The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies". Expert Opinion on Drug Discovery. 18 (5): 515–526. doi:10.1080/17460441.2023.2200245. PMID   37042028.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.